CD63 and neoplasm: In a metastatic human xenograft breast cancer mouse model, Nishida et al. demonstrated that co-administration of therapeutic antibodies with human-specific anti-CD9 and anti-CD63 antibodies led to efficient removal of tumor-derived EVs by macrophages, resulting in a dramatic reduction in tumor burden [111].